RxDoctor Payments DataLook up a doctor →

Duane Dilworth, MD

Dermatology · Saint Louis, MONPI 1730507617

Payments from drug & device makers

$300,768in general payments, 2019–2025

Across 1,538 payments — averaging $195.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Galderma Laboratories, L.p.$95K
  • Lilly USA, LLC$67K
  • Pfizer$51K
  • Arcutis Biotherapeutics, Inc.$34K
  • Novartis$16K
  • E.r. Squibb & Sons, L.L.C.$7K
  • plus $30K from 34 others

What the payments were for

  • Consulting fees$45,18116%
  • Speaking & faculty fees$185,74264%
  • Travel & lodging$15,2825%
  • Food & beverage$41,09514%
  • Education$7050%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$300,768 in reported general payments places this provider in the 95th percentile of 263 dermatology providers in Missouri.

See all dermatology providers in Missouri

Medicare billing

Part B allowed, 2024
$198,057
Medicare patients
702
Services billed
3,076

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab41$197,692
Cosentyx Unoready PenSecukinumab18$177,800
Dupixent SyringeDupilumab17$104,664
AdbryTralokinumab-Ldrm14$51,900
OpzeluraRuxolitinib Phosphate12$24,009
ZoryveRoflumilast12$10,267
Metronidazole52$5,742
Ketoconazole264$4,059
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc58$2,892
Tretinoin45$2,676
Fluocinolone Acetonide56$2,565
Fluocinonide68$2,443
Doxycycline Hyclate51$1,710
Tacrolimus15$1,636
Ciclopirox40$1,595

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
LEO Pharma Inc.Adbry$1,602$51,90014 claims
Incyte CorporationOpzelura$1,719$24,00912 claims
Arcutis Biotherapeutics, Inc.Zoryve$33,703$10,26712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 263 dermatology providers in Missouri.

Other dermatology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →